Ginkgo Bioworks Holdings, Inc.

As of June 30, 2026, Ginkgo Bioworks Holdings, Inc. Class A carries a market capitalization of 8.57B, placing it among publicly traded companies globally. Its enterprise value stands at 10.35B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Ginkgo Bioworks Holdings, Inc. Class A's next confirmed earnings release is scheduled for November 16, 2026.

As of June 30, 2026, Ginkgo Bioworks Holdings, Inc. Class A has 61.80M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 4.03, and the price-to-book ratio stands at 1.17.

These figures are as of June 30, 2026. The EV/Sales ratio of 5.29 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 10.35B versus a market cap of 8.57B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Ginkgo Bioworks Holdings, Inc. Class A maintains a current ratio of 4.57, meaning it holds 4.6x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Ginkgo Bioworks Holdings, Inc. Class A posted a negative return on equity (ROE) of -56.29, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -26.19, reflecting losses generated across the asset base. The company generates approximately 3.42M in revenue per employee across its workforce of 572.25, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Ginkgo Bioworks Holdings, Inc. Class A recorded an income tax benefit of -10.38M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -5.16B and -5.08B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on July 6, 2026, Ginkgo Bioworks Holdings, Inc. Class A's stock has declined approximately 22.91% over the past 52 weeks.

Over the twelve months ended June 30, 2026, Ginkgo Bioworks Holdings, Inc. Class A generated 1.95B in revenue and converted that into -5.08B in net income, yielding earnings per share of -90.61. EBITDA reached -4.13B, while operating income came in at -5.04B.

As of June 30, 2026, Ginkgo Bioworks Holdings, Inc. Class A holds 5.28B in cash and equivalents against 7.06B in total debt, resulting in a net debt position of -1.48B. Total book value stands at 7.34B, with working capital of 4.54B providing operational flexibility.

Ginkgo Bioworks Holdings, Inc. Class A produced -2.97B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -79.62M in capital expenditures, free cash flow totaled -3.05B - equivalent to -53.71 per share.

Over the twelve months ended June 30, 2026, Ginkgo Bioworks Holdings, Inc. Class A posted a gross margin of 77.72, reflecting its pricing power and cost economics. The operating margin of -257.67 and net profit margin of -259.96 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -38.75: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -7.05, meaning Ginkgo Bioworks Holdings, Inc. Class A raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Ginkgo Bioworks Holdings, Inc. Class A's most recent stock split took place on August 20, 2024 with a 40:1 split ratio.

As of June 30, 2026, Ginkgo Bioworks Holdings, Inc. Class A has an Altman Z-Score of -9.34, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.